The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 46 | 61 |
Growth
|
n/a | n/a | 45 | 3 |
Safety
|
n/a | n/a | 100 | 98 |
Sentiment
|
n/a | n/a | 24 | 75 |
|
n/a | n/a | 51 | 77 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
n/a | n/a | 20 | 7 |
Opinions Change
|
n/a | n/a | 50 | 91 |
Pro Holdings
|
n/a | n/a | 22 | 76 |
Market Pulse
|
n/a | n/a | 52 | 63 |
Sentiment
|
n/a | n/a | 24 | 75 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 46 | 61 |
Growth
|
n/a | n/a | 45 | 3 |
|
n/a | n/a | 100 | 98 |
Combined
|
n/a | n/a | 84 | 53 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
n/a | n/a | 19 | 27 |
Price vs. Earnings (P/E)
|
n/a | n/a | 51 | 74 |
Price vs. Book (P/B)
|
n/a | n/a | 86 | 97 |
Dividend Yield
|
n/a | n/a | 42 | 49 |
Value
|
n/a | n/a | 46 | 61 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
n/a | n/a | 19 | 23 |
Profit Growth
|
n/a | n/a | 12 | 9 |
Capital Growth
|
n/a | n/a | 71 | 22 |
Stock Returns
|
n/a | n/a | 91 | 29 |
Growth
|
n/a | n/a | 45 | 3 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
n/a | n/a | 97 | 90 |
Refinancing
|
n/a | n/a | 83 | 95 |
Liquidity
|
n/a | n/a | 86 | 76 |
|
n/a | n/a | 100 | 98 |
Discover high‑ranked alternatives to Taisho Pharmaceutical Holdings and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.